An update from Benitec Biopharma (BNTC) is now available.
Benitec Biopharma Inc. has released promising interim results from its BB-301 Phase 1b/2a study, showcasing the effects at the 180-day mark for the first subject treated with a low dose of their investigational drug, BB-301. This announcement could be a significant milestone for investors and those keeping an eye on the biopharmaceutical sector’s innovative therapies.
See more data about BNTC stock on TipRanks’ Stock Analysis page.
